18 Columvi® (glofitamab): Three-year follow-up and subgroup analyses from the phase III STARGLO study show continued superior survival outcomes with Columvi in combination with gemcitabine and ...
Findings further demonstrate the effectiveness of Roche's approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback